IL320391A - Modulators and uses thereof - Google Patents

Modulators and uses thereof

Info

Publication number
IL320391A
IL320391A IL320391A IL32039125A IL320391A IL 320391 A IL320391 A IL 320391A IL 320391 A IL320391 A IL 320391A IL 32039125 A IL32039125 A IL 32039125A IL 320391 A IL320391 A IL 320391A
Authority
IL
Israel
Prior art keywords
smc
modulator
retinal
disease
ccr1
Prior art date
Application number
IL320391A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Publication of IL320391A publication Critical patent/IL320391A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL320391A 2022-10-24 2023-10-24 Modulators and uses thereof IL320391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263380675P 2022-10-24 2022-10-24
PCT/IL2023/051103 WO2024089691A1 (en) 2022-10-24 2023-10-24 Modulators and uses thereof

Publications (1)

Publication Number Publication Date
IL320391A true IL320391A (en) 2025-06-01

Family

ID=90830247

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320391A IL320391A (en) 2022-10-24 2023-10-24 Modulators and uses thereof

Country Status (3)

Country Link
EP (1) EP4608403A4 (de)
IL (1) IL320391A (de)
WO (1) WO2024089691A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US9314450B2 (en) * 2011-01-11 2016-04-19 Dimerix Bioscience Pty Ltd. Combination therapy
CN103357017B (zh) * 2013-03-07 2015-06-10 首都医科大学附属北京同仁医院 met-RANTES在制备治疗遗传性视网膜变性药物中的应用
CN112386696A (zh) * 2019-08-13 2021-02-23 贵州百灵企业集团制药股份有限公司 一种治疗胰岛素抵抗的靶点及其应用
WO2022079322A1 (en) * 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage

Also Published As

Publication number Publication date
EP4608403A1 (de) 2025-09-03
WO2024089691A1 (en) 2024-05-02
EP4608403A4 (de) 2026-04-01

Similar Documents

Publication Publication Date Title
US11197856B2 (en) Bicyclic compounds and methods for their use in treating autism
JP2000514402A (ja) Ｖｅｇｆに関連する目の病気に関する治療処置
US20220362236A1 (en) Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US20240245680A1 (en) Methods of Treating Retinal Vasculopathies
Sun et al. Aqueous inflammation and ischemia-related biomarkers in neovascular glaucoma with stable iris neovascularization
CN106714821B (zh) Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
You et al. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy
US9457013B2 (en) Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor
WO2024089691A1 (en) Modulators and uses thereof
WO2011087491A2 (en) Parstatin peptides and uses thereof
KR20180109278A (ko) 종간 교차활성을 지닌 mTOR를 표적으로 하는 siRNA를 함유하는 망막혈관질환 치료용 조성물
EP3096780A1 (de) Abl1-hemmer zur behandlung und prävention von neovaskularisierung
Manhui et al. Crosstalk Between RPE Cells and Choroidal Endothelial Cells via the ANXA1/FPR2/SHP2/NLRP3 Inflammasome/Pyroptosis Axis Promotes Choroidal Neovascularization
Rudraraju Mechanisms of Endothelial-Barrier Regulation and Vascular Permeability in Ocular Inflammatory Diseases
US20230077811A1 (en) Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
JP2024178773A (ja) 異常血管新生の治療剤または予防剤、および、その利用
WO2009039388A2 (en) Compositions and methods for detecting and treating ophthalmic disorders
Adis et al. 4. Prostanoid receptor gene expression in human and murine anterior ocular segment
Roddy et al. 7. Stanniocalcin-1, a novel ocular hypotensive agent with capacity for sustained intraocular pressure reduction
Liu et al. The Adenosine A2A Receptor Antagonist KW6002 Mitigates Aldosterone-induced Central Serous Chorioretinopathy in Mice
CN121891351A (zh) Fgf2抑制剂在制备治疗视网膜和脉络膜新生血管疾病药物中的应用
HK40057869A (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3204031A2 (de) Verwendung von zelldurchlässigen peptidhemmern des jnk-signaltransduktionsweges zur behandlung verschiedener krankheiten
Platón et al. p75 NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa
WO2011065968A1 (en) Use of monocyte chemoattractant compounds to treat ocular disorders